Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by a...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/9/4/145 |
id |
doaj-8798b1fe9cdc4fa18411d8387cb72231 |
---|---|
record_format |
Article |
spelling |
doaj-8798b1fe9cdc4fa18411d8387cb722312020-11-25T02:23:05ZengMDPI AGAntibiotics2079-63822020-03-01914514510.3390/antibiotics9040145Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic PatientsKosuke Kaji0Soichiro Saikawa1Hiroaki Takaya2Yukihisa Fujinaga3Masanori Furukawa4Koh Kitagawa5Takahiro Ozutsumi6Daisuke Kaya7Yuki Tsuji8Yasuhiko Sawada9Hideto Kawaratani10Kei Moriya11Tadashi Namisaki12Takemi Akahane13Akira Mitoro14Hitoshi Yoshiji15Department of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanRifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by ammonia level, neuropsychological testing, endotoxin activity (EA), and serum proinflammatory cytokines at baseline and after four weeks of rifaximin treatment (1200 mg/day). Intestinal permeability was indicated by serum soluble CD163 (sCD163), mannose receptor (sMR), and zonulin levels. To evaluate the gut microbiome, 16S ribosomal RNA gene sequencing was applied. Rifaximin ameliorated hyperammonemia and cognitive dysfunction, although it did not change the serum proinflammatory cytokine levels. It decreased EA levels as well as serum levels of sCD163 and sMR, but not zonulin, and both decreases in sCD163 and sMR showed positive correlations with EA decrease (ΔsCD163: Correlation coefficient (R) = 0.680, <i>p</i> = 0.023; ΔsMR: R = 0.613, <i>p</i> = 0.014, vs. ΔEA). Gut microbial analysis revealed that the richness and complexity of species were unchanged while the abundance of the <i>Streptococcus</i> genus was reduced after treatment with rifaximin. Collectively, rifaximin alleviated HE and endotoxemia with improved intestinal hyperpermeability in patients with decompensated cirrhosis, and this effect is partially involved in a gut microbial change.https://www.mdpi.com/2079-6382/9/4/145cirrhosisendotoxinmicrobiomerifaximin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kosuke Kaji Soichiro Saikawa Hiroaki Takaya Yukihisa Fujinaga Masanori Furukawa Koh Kitagawa Takahiro Ozutsumi Daisuke Kaya Yuki Tsuji Yasuhiko Sawada Hideto Kawaratani Kei Moriya Tadashi Namisaki Takemi Akahane Akira Mitoro Hitoshi Yoshiji |
spellingShingle |
Kosuke Kaji Soichiro Saikawa Hiroaki Takaya Yukihisa Fujinaga Masanori Furukawa Koh Kitagawa Takahiro Ozutsumi Daisuke Kaya Yuki Tsuji Yasuhiko Sawada Hideto Kawaratani Kei Moriya Tadashi Namisaki Takemi Akahane Akira Mitoro Hitoshi Yoshiji Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients Antibiotics cirrhosis endotoxin microbiome rifaximin |
author_facet |
Kosuke Kaji Soichiro Saikawa Hiroaki Takaya Yukihisa Fujinaga Masanori Furukawa Koh Kitagawa Takahiro Ozutsumi Daisuke Kaya Yuki Tsuji Yasuhiko Sawada Hideto Kawaratani Kei Moriya Tadashi Namisaki Takemi Akahane Akira Mitoro Hitoshi Yoshiji |
author_sort |
Kosuke Kaji |
title |
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients |
title_short |
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients |
title_full |
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients |
title_fullStr |
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients |
title_full_unstemmed |
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients |
title_sort |
rifaximin alleviates endotoxemia with decreased serum levels of soluble cd163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients |
publisher |
MDPI AG |
series |
Antibiotics |
issn |
2079-6382 |
publishDate |
2020-03-01 |
description |
Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by ammonia level, neuropsychological testing, endotoxin activity (EA), and serum proinflammatory cytokines at baseline and after four weeks of rifaximin treatment (1200 mg/day). Intestinal permeability was indicated by serum soluble CD163 (sCD163), mannose receptor (sMR), and zonulin levels. To evaluate the gut microbiome, 16S ribosomal RNA gene sequencing was applied. Rifaximin ameliorated hyperammonemia and cognitive dysfunction, although it did not change the serum proinflammatory cytokine levels. It decreased EA levels as well as serum levels of sCD163 and sMR, but not zonulin, and both decreases in sCD163 and sMR showed positive correlations with EA decrease (ΔsCD163: Correlation coefficient (R) = 0.680, <i>p</i> = 0.023; ΔsMR: R = 0.613, <i>p</i> = 0.014, vs. ΔEA). Gut microbial analysis revealed that the richness and complexity of species were unchanged while the abundance of the <i>Streptococcus</i> genus was reduced after treatment with rifaximin. Collectively, rifaximin alleviated HE and endotoxemia with improved intestinal hyperpermeability in patients with decompensated cirrhosis, and this effect is partially involved in a gut microbial change. |
topic |
cirrhosis endotoxin microbiome rifaximin |
url |
https://www.mdpi.com/2079-6382/9/4/145 |
work_keys_str_mv |
AT kosukekaji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT soichirosaikawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT hiroakitakaya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT yukihisafujinaga rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT masanorifurukawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT kohkitagawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT takahiroozutsumi rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT daisukekaya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT yukitsuji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT yasuhikosawada rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT hidetokawaratani rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT keimoriya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT tadashinamisaki rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT takemiakahane rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT akiramitoro rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients AT hitoshiyoshiji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients |
_version_ |
1724860004641538048 |